First US mRNA flu vaccine signals a new era for vaccines
TL;DR
FDA approves mFLUSIVA, the United States’ first mRNA influenza vaccine, marking a milestone for the platform after a year of funding reversals; unlike egg-based vaccines, it can be updated in two to three months and deployed closer to flu season, hinting at future breakthroughs across vaccines and therapies, though real-world uptake will depend on access, cost, and regulatory guidance.
- The strange reason flu shots have been so hard to improve vox.com
- There’s a new flu shot for adults 50 and older. Should you get it? San Francisco Chronicle
- A new flu vaccine geared to older people is coming soon NPR
- The new mRNA flu shot mFlusiva is more effective. Why doctors worry Long Islanders may not try it. Newsday
- What to know about the first mRNA-based flu shot approved by the FDA The Washington Post
Want the full story? Read the original reporting
Read on vox.com